Abstract
An aberrant right subclavian artery (ARSA) is in most cases an asymptomatic aortic arch anomaly. However, dysphagia, aneurysm formation (ARSAA), associated Kommerell diverticulum, or cerebellar/arm malperfusion may require invasive therapy. Large-scale clinical trials do not exist in current literature. We report our patient's outcome of a single-center experience and delineate indications for treatment and surgical techniques. A single-center retrospective study was conducted between January 1, 2012 through March 1, 2018. Symptomatic or asymptomatic patients with ARSAA who received invasive treatment at the Department for Vascular and Endovascular Surgery, University Hospital Dusseldorf, Germany were included. Eight patients (4 men, 63±14 (39-78) years) were treated with single-stage (n=4) or multistage (n=4) procedures. Treatment for ARSAA (n=4) included ARSA revascularization (subclavian-carotid transposition (SCT)=3; carotid-subclavian bypass (CSB)=1), aortic arch debranching (left SCT=2, bilateral aorto-carotid bypass+left CSB=1, right-to-left CSB+left-carotid-to-bypass transposition=1), and thoracic endovascular aortic repair (TEVAR; n=4). Other strategies included SCT for dysphagia (n=2) or subclavian steal syndrome (n=1) and balloon angioplasty for arm claudication (n=1). Complications involved vascular access (n=2) and each one partial common carotid artery overstenting without stroke during TEVAR and Horner syndrome after SCT. Mean follow-up was 23±26 (9-67) months. After 7 months, 1 patient required vertebral artery coiling due to type II endoleak with ARSAA progression. Overall mortality was 0%. Technical and clinical success rates were 100%. Surgical concepts for ARSA aim on preventing aneurysm rupture and alleviate dysphagia or ischemic symptoms. To generate satisfying patient outcomes, individualized therapy planning in specialized centers is vital.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call